DMK Pharmaceuticals Corporation (DMKPQ)

Market Cap	10.00 -100.0%
Revenue (ttm)	3.62M +150.3%
Net Income	-22.41M
EPS	-6.39
Shares Out	10.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	443
Average Volume	12,279
Open	0.0000
Previous Close	n/a
Day's Range	0.0000 - 0.0000
52-Week Range	n/a
Beta	37.05
RSI	50.38
Earnings Date	n/a

About DMK Pharmaceuticals

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other aller...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Employees: 12
• Stock Exchange: OTCMKTS
• Ticker Symbol: DMKPQ

Financial Performance

In 2022, DMK Pharmaceuticals's revenue was $4.76 million, an increase of 115.34% compared to the previous year's $2.21 million. Losses were -$26.48 million, -42.22% less than in 2021.